The U.S. Food and Drug Administration (FDA) has approved lenacapavir (brand name Yeztugo) as the first ever twice yearly injectable HIV prevention treatment, a decision announced on June 18, 2025 that could reshape global efforts to end the HIV epidemic.
The approval marks a major step forward in HIV pre exposure prophylaxis (PrEP), offering a long acting alternative to daily pills and frequent injections. Health experts say the development could significantly improve treatment adherence and global prevention outcomes, particularly in high risk populations.
But beyond regulatory approval, the real impact lies in how this innovation changes the way prevention is delivered.
A Major Shift in HIV Prevention Strategy
For decades, HIV prevention has relied heavily on daily oral PrEP medication, which has proven highly effective when taken consistently. However, maintaining strict daily adherence has remained a major challenge worldwide.
Lenacapavir changes that equation.
Unlike traditional treatments, Yeztugo requires just two injections per year, dramatically reducing the burden on patients. This shift could help address long-standing barriers such as:
- Missed daily doses
- Limited access to healthcare facilities
- Privacy concerns around medication use
- Social stigma associated with HIV prevention
This raises a critical question: what happens when prevention becomes nearly effortless?
Near Complete Protection in Clinical Trials
Clinical trial data has generated significant optimism among researchers and public health experts.
In the PURPOSE 1 trial, which focused on women in Uganda and South Africa, researchers reported zero HIV infections in participants receiving lenacapavir.
That level of protection is among the strongest ever observed in HIV prevention research.
Beyond its effectiveness, lenacapavir represents a scientific breakthrough in how it works. It is the first HIV-1 capsid inhibitor, targeting a different part of the virus compared to earlier drugs that typically focus on single enzymes.
This innovation could be especially important for individuals who struggle with consistent medication routines, offering a long acting and discreet prevention option.
Why Long Acting PrEP Could Transform Public Health
One of the most significant advantages of Yeztugo is its simplicity. With only two injections per year, it reduces the need for constant engagement with healthcare systems.
Beyond convenience, experts highlight another key benefit: privacy.
For many people, daily HIV prevention medication can carry stigma or raise concerns about disclosure. A long acting injectable offers a more discreet alternative, potentially increasing uptake among populations who have previously avoided PrEP.
This shift could have wide reaching implications for global HIV prevention strategies.
The Challenge of Access and Affordability
Despite widespread excitement, major questions remain around cost and global access.
In high income countries, the current pricing of lenacapavir presents a significant barrier. Public health organizations warn that without broad affordability strategies, the impact of this breakthrough could be uneven across regions.
However, efforts are already underway to address this gap. Gilead Sciences has partnered with generic manufacturers and global health organizations, including the Global Fund,
to expand access in lower income countries.
Still, experts caution that distribution and affordability will ultimately determine how transformative this drug becomes on a global scale.
A Turning Point in the Fight Against HIV
The approval of Yeztugo (lenacapavir) is being widely described as a milestone in HIV prevention research. More than just a new treatment option, it represents a shift toward long acting, user friendly prevention tools that could reshape global health strategies.
While challenges around pricing and distribution remain, the scientific achievement is undeniable.
As researchers and policymakers work to expand access, lenacapavir offers something that has long defined progress in HIV care: renewed hope that ending the epidemic is no longer a distant goal, but an achievable one.
